You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.


Kedrion names Val Romberg as new CEO

Castelvecchio Pascoli (Lucca) - 05 October 2020 - The Board of Directors of Kedrion S.p.A. is pleased to welcome Val Romberg as the new CEO of Kedrion.  Val Romberg’s career has spanned over nearly forty years in the pharmaceutical industry – specifically in the plasma derivatives sector - in companies such as CSL Behring, West Pharmaceutical Services and Aventis Behring. His last position, which ended in 2019, was as Executive Vice President, Manufacturing and Planning.

Paolo Marcucci will continue to be Chairman of the company and will remain in charge of Strategy, Business Development, and External Relations. Mr. Marcucci said: "Val Romberg's leadership skills and experience - particularly in Operations, R&D and Manufacturing - make him a great fit with the mission and values of our company."

Mr. Marcucci added: “Mr. Romberg’s knowledge and authority in the plasma industry will ensure a valuable guide to Kedrion for a successful future. Val Romberg will be completely dedicated to managing the challenges outlined in our strategic plans and has the full support of the Board of Directors and of all Kedrion’s shareholders. I am looking forward to working with Val and live together this new season of our company.”

For more information please contact: [email protected]